NYSEAMERICAN:KAPA Kairos Pharma Q4 2025 Earnings Results & Report $0.67 -0.07 (-9.74%) Closing price 04:10 PM EasternExtended Trading$0.67 +0.00 (+0.06%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Kairos Pharma reported Q4 2025 earnings on March 31, 2026. The company reported EPS of -$0.49. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateMarch 31, 2026TimeAfter Market ClosesConference Call7:00 AM ET Kairos Pharma EPS ResultsActual EPS-$0.49Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AKairos Pharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesAnnual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsAnnual report(10-K) Kairos Pharma Q4 2025 Earnings FAQ Did Kairos Pharma beat earnings estimates for Q4 2025? Kairos Pharma (NYSEAMERICAN:KAPA) reported earnings of -$0.49 per share for Q4 2025. The report was announced on Tuesday, March 31, 2026. Kairos Pharma Earnings HeadlinesKairos Pharma Reports Interim PFS Benefit For ENV-105 In Phase 2 Prostate Cancer TrialOctober 6, 2026 | rttnews.comKairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate CancerOctober 6, 2026 | finance.yahoo.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.October 15 at 1:00 AM | Stansberry Research (Ad)Kairos Pharma to Present and Moderate at Discovery on Target Conference in Boston, MASeptember 23, 2026 | marketscreener.comMKairos Pharma consensus price target increased by 600.00% to $49.98September 15, 2026 | msn.comKairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 9, 2026 | finance.yahoo.comSee More Kairos Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Kairos Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kairos Pharma and other key companies, straight to your email. Email Address About Kairos PharmaKairos Pharma (NYSEAMERICAN:KAPA) is a clinical-stage biopharmaceutical company focused on developing therapies for cancer, particularly treatments intended to address resistance to existing immunotherapies and other oncology treatments. The company’s work centers on immuno-oncology and the development of investigational drug candidates for patients with difficult-to-treat cancers. Kairos Pharma is advancing a pipeline of experimental therapies designed to modify the tumor microenvironment and improve the body’s immune response against cancer. Its programs are in development and remain subject to clinical testing, regulatory review and other requirements before any product can be commercialized. The company is based in the United States and serves the biopharmaceutical and oncology markets through its research and development activities. Publicly available information about its operating history, geographic reach and leadership is limited; therefore, specific details about its management team and commercial operations are not included here.View Kairos Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin PressureASML Can’t Keep Up With AI Demand—Why That's a Good ThingCiti Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling? Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
